Tesamorelin: The FDA-Approved GHRH Analog With Clinical Evidence for Visceral Fat Reduction

What it is

Your brain sends a hormone called GHRH to the pituitary, and the pituitary answers with growth hormone. Natural GHRH lasts a few minutes. Tesamorelin is the full 44-amino-acid GHRH molecule with a small chemical cap on one end that protects it from enzymes, so it lasts about 26 minutes: long enough to work, still short enough that it is injected once a day.

Theratechnologies sells it as Egrifta. The FDA approved it in 2010 for one specific problem: the deep abdominal fat that some people with HIV accumulate as a side effect of antiretroviral drugs. Among GHRH-type peptides, it is the only one with a current approval. Sermorelin had one and lost it; CJC-1295 never got one.

That approval is narrow, but the mechanism is not. Growth hormone burns fat wherever it finds it, and it finds it fastest in the deep belly fat around the organs. That is why tesamorelin gets prescribed off-label to people who do not have HIV.

What it is studied for

The approved use: visceral fat in HIV lipodystrophy. Beyond that, liver fat in the same population, and, in one trial, memory and thinking in older adults. The off-label use for ordinary age-related belly fat has never had a trial of its own.

What the evidence actually shows

In humans

Two Phase III trials, 816 people combined, gave 2 mg of tesamorelin or placebo daily to HIV-positive adults with excess belly fat. Over 26 weeks, visceral fat fell by about 15 to 18% in the treated group, measured by CT scan, which is the most precise way to measure it. Subcutaneous fat, the kind you can pinch, did not change much, and lean mass held or rose slightly. IGF-1 came back into the normal range, triglycerides improved modestly, and the main complaint was sore injection sites (Falutz et al., 2007).

A later trial in HIV patients with fatty liver found tesamorelin reduced liver fat by roughly a third relative to placebo and improved markers of liver scarring (Stanley et al., 2014).

The cognitive finding comes from a single 20-week trial in 137 adults aged 55 to 87, some with mild memory impairment and some without. The tesamorelin group did better on tests of executive function and, in a subgroup, verbal memory (Baker et al., 2012). It is one trial, it was short, and it has not been repeated. It is a lead, not a result.

What is missing

There is no trial of tesamorelin for belly fat in people without HIV. The off-label use rests on the assumption that the same mechanism produces the same effect in a different population. That is a reasonable assumption and it is still an assumption.

From user reports

People prescribed it off-label describe a slow loss of belly fat over months, better sleep, and the same joint aches and water retention the trials recorded. Some clinics cycle it, six months on and a couple off, on the theory that the pituitary needs a rest; the approved use is continuous, and no trial has compared the two.

How it works

Tesamorelin lands on the same pituitary receptor as natural GHRH and triggers a pulse of growth hormone, which the body’s own rhythm then clears. Growth hormone tells fat cells to release their stores, and deep belly fat responds most because those cells carry more growth hormone and adrenaline receptors than fat elsewhere. Growth hormone also raises IGF-1, which is where the lean-mass and blood-sugar effects come from.

Because it produces a pulse rather than a constant level, it behaves more like the body’s own signal than CJC-1295 with DAC, which keeps the receptor stimulated for a week.

How it is used in studies

The approved dose is 2 mg under the skin of the abdomen once a day, rotating sites. Off-label prescriptions run 1 to 2 mg daily, in the morning fasted or at bedtime. Compounded or research-grade product is mixed with bacteriostatic water and kept refrigerated; see the storage and reconstitution guide.

Side effects and unknowns

From the Phase III data: injection-site redness, itching, or swelling in about a quarter of people; joint pain in about 13%; muscle aches, swelling in the hands and feet, and tingling in a smaller share. Those last three are growth hormone effects and show up with every drug in this class.

Growth hormone opposes insulin, so blood sugar can drift up. In the trials the effect was small; anyone with prediabetes or diabetes should have fasting glucose and HbA1c watched. IGF-1 should be checked too, both to confirm the drug is working and to keep it from running above normal, since chronically high IGF-1 has a theoretical link to cancer risk. Standard monitoring, because the drug is approved and has a label, is IGF-1, glucose, HbA1c, and a check on fluid retention.

The unknown is long-term use outside the approved population. The HIV trials ran a year or so. What ten years of growth hormone stimulation does to a healthy 55-year-old’s metabolism or cancer risk has not been measured.

How it compares

• Sermorelin: the same idea with a shorter life (10 to 20 minutes), a longer safety record, and weaker fat-loss data. The conservative pick.
• CJC-1295: similar stability without DAC, weekly dosing with DAC, no approval, and almost no fat-loss data. Cheaper as a research chemical.
• Ipamorelin: works on the ghrelin receptor instead, so people stack it with GHRH-type peptides rather than choosing between them. See the muscle growth guide.
• MK-677: an oral ghrelin mimetic; convenient, raises appetite, no fat-loss trial data.
• Semaglutide and tirzepatide: produce far more total weight loss through appetite; tesamorelin is narrower, aimed at visceral fat specifically. See the fat loss guide.

Legal status

FDA approved as Egrifta for HIV-associated lipodystrophy, prescription only. Off-label prescribing for other uses is legal; insurance rarely covers it. Also sold by compounding pharmacies and as a research chemical. WADA bans GHRH and its analogs in and out of competition.

Bottom line

Tesamorelin is the GHRH peptide with real evidence: two Phase III trials, an FDA approval, a known side-effect list, and a clear effect on the fat that matters most for metabolic health. The evidence is for people with HIV. Everyone else using it is extrapolating, on a sound mechanism, from a trial that did not include them.

References

1. Falutz J, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. PubMed
2. Stanley TL, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. PubMed
3. Baker LD, et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol.

See also

• Peptide
  AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

  AOD-9604 is the tail end of the growth hormone molecule, kept for its fat-burning signal and stripped of everything else. Mice lost half their fat on it; a 300-person human trial missed its primary goal.

• Peptide
  CJC-1295: What the Evidence Says About This GHRH Analog

  CJC-1295 is a longer-lasting version of GHRH, the signal that tells the pituitary to release growth hormone. The DAC form raised GH and IGF-1 for days in one small trial; the no-DAC form (Mod GRF 1-29) has no human trial of its own.

• Peptide
  Ipamorelin: What the Evidence Says About This Selective GH Secretagogue

  Ipamorelin is a five-amino-acid peptide that mimics ghrelin to release a pulse of growth hormone, and unlike its predecessors does it without raising cortisol, prolactin, or hunger. Human data: one dosing study and one abandoned surgery trial.